High Blood Pressure & Vascular Health • ICD-10-CM D21.9
Vascular hamartoma
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM D21.9 • 7 Linked .gov / PubMed Citations
•
Governance: Dr. Marcus Thorne, MD, FACC (NPI #1184629314)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Vascular hamartoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinical triage of Vascular hamartoma (D21.9) in Blood Pressure relies on segmental arterial Doppler in Vascular hamartoma (D21.9: waveforms), guiding step-wise therapeutic adjustments toward Home Seated Blood in Vascular hamartoma (D21.9: Pressure) (< 120/75 mmHg (D21.9)).
- 2 Real-world patient consensus: Clinical coding for Vascular hamartoma uses ICD-10 D21.9 across Blood Pressure specialty care.
- 3 Typical cash cost range: Workup highlights for Vascular hamartoma (D21.9): segmental arterial Doppler in Vascular hamartoma (D21.9: waveforms).
- 4 Top reported side effects / signs: Follow-up benchmark in Vascular hamartoma: maintaining Urine Albumin-to-Creatinine Ratio [Vascular hamartoma D21.9] within < 15 mg/g (D21.9).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Vascular hamartoma
What Is Vascular hamartoma?
Clinical triage of Vascular hamartoma (D21.9) in Blood Pressure relies on segmental arterial Doppler in Vascular hamartoma (D21.9: waveforms), guiding step-wise therapeutic adjustments toward Home Seated Blood in Vascular hamartoma (D21.9: Pressure) (< 120/75 mmHg (D21.9)).
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Vascular hamartoma (code D21.9) is arterial smooth-muscle hypertrophy [Vascular hamartoma D21.9], which High Blood Pressure & Vascular Health clinicians address while surveilling Urine Albumin-to-Creatinine Ratio [Vascular hamartoma D21.9] (< 15 mg/g (D21.9)).
Common Symptoms & Clinical Signs
- • Presentation of Vascular hamartoma (D21.9): cold distal extremities in Vascular hamartoma (D21.9: or diminished peripheral)
- • Secondary Vascular hamartoma clinical sign: persistently elevated home in Vascular hamartoma (D21.9: or clinic blood)
- • Symptom flares in Vascular hamartoma correlating with Urine Albumin-to-Creatinine Ratio [Vascular hamartoma D21.9] deviation outside < 15 mg/g (D21.9)
- • Functional blood pressure impact requiring segmental arterial Doppler in Vascular hamartoma (D21.9: waveforms) evaluation (D21.9)
Vascular hamartoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D21.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Vascular hamartoma D21.9] | < 15 mg/g (D21.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Vascular hamartoma (D21.9: Pressure) | < 120/75 mmHg (D21.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Vascular hamartoma D21.9] | 1.00 – 1.30 (D21.9) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Vascular hamartoma
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Nufymco (Ranibizumab-Leyk) Nufymco • RxCUI RXN-B707102172 | Vascular Endothelial Growth Factor Inhibitor | 82% | $0.5600 | $ 48.82 /mo |
| Jobevne (Bevacizumab-Nwgd) Jobevne • RxCUI 2712055 | Vascular Endothelial Growth Factor Inhibitor | 94% | $1.0200 | $ 81.94 /mo |
| Ranibizumab Lucentis, Susvimo • RxCUI 1864423 | Vascular Endothelial Growth Factor Inhibitor | 75% | $0.6200 | $ 33.61 /mo |
| Bevacizumab-Vikg Lytenava • RxCUI RXN-82491025-2275 | Vascular Endothelial Growth Factor Inhibitor | 85% | $2.9000 | $ 125.95 /mo |
| Aflibercept Eylea, Enzeevu • RxCUI 1232154 | Vascular Endothelial Growth Factor Inhibitor | 91% | $3.5400 | $ 151.87 /mo |
| Zaltrap (Ziv-Aflibercept) Zaltrap • RxCUI 1723189 | Vascular Endothelial Growth Factor Inhibitor | 80% | $2.4000 | $ 181.30 /mo |
| Bevacizumab-Bvzr Zirabev • RxCUI RXN-00690342-2280 | Vascular Endothelial Growth Factor Inhibitor | 83% | $1.4200 | $ 66.01 /mo |
| Yesafili (Aflibercept-Jbvf) Yesafili • RxCUI RXN-B83257035 | Vascular Endothelial Growth Factor Inhibitor | 94% | $2.7600 | $ 207.22 /mo |
| Ranibizumab-Leyk Nufymco • RxCUI RXN-707102172-2427 | Vascular Endothelial Growth Factor Inhibitor | 91% | $3.2700 | $ 140.94 /mo |
| Pavblu (Aflibercept-Ayyh) Pavblu • RxCUI 2696260 | Vascular Endothelial Growth Factor Inhibitor | 77% | $0.3500 | $ 33.70 /mo |
| Lytenava (Bevacizumab-Vikg) Lytenava • RxCUI RXN-B82491025 | Vascular Endothelial Growth Factor Inhibitor | 87% | $0.6900 | $ 58.18 /mo |
| Susvimo (Ranibizumab) Susvimo • RxCUI RXN-B50242078 | Vascular Endothelial Growth Factor Inhibitor | 91% | $0.6300 | $ 53.86 /mo |
| Ramucirumab Cyramza • RxCUI RXN-00027678-2828 | Vascular Endothelial Growth Factor Receptor 2 Antagonist | 80% | $2.1200 | $ 94.36 /mo |
| Cyramza (Ramucirumab) Cyramza • RxCUI RXN-B00027678 | Vascular Endothelial Growth Factor Receptor 2 Antagonist | 86% | $3.1800 | $ 237.46 /mo |
| Faricimab Vabysmo • RxCUI 2591588 | FDA Prescription Therapeutic Agent | 92% | $1.5200 | $ 70.06 /mo |
| Ahzantive (Aflibercept-Mrbb) Ahzantive • RxCUI RXN-B850062908 | Vascular Endothelial Growth Factor Inhibitor | 87% | $1.9000 | $ 145.30 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vascular hamartoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Achieved blood pressure and heart and blood vessel outcomes in high-risk: What a 8,407-Participant Study Found Mean achieved SBP less than 120 mm Hg during treatment was associated with increased risk of heart and blood vessel outcomes except for heart attack and stroke. Lancet (London, England) • 2017-06-03 • Meta-Analysis | N = 8,407 | 99/100 | PMID 28390695 ↗ |
| New Insights on Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and: What a 21,135-Participant Study Found GLP1RA therapy when compared to placebo reduced all-cause mortality in high heart and blood vessel risk patients with type 2 diabetes. Current diabetes reviews • 2018-01-15 • Meta-Analysis | N = 21,135 | 99/100 | PMID 28413990 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
| New Insights on Association between testosterone replacement therapy and heart and blood vessel: What a 11,502-Participant Study Found Our analysis indicates that for patients with hypogonadism, testosterone replacement therapy does not increase the CVD risk and all-cause mortality. Progress in cardiovascular diseases • 2024-01-15 • Meta-Analysis | N = 11,502 | 99/100 | PMID 38589271 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Vascular hamartoma Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Vascular hamartoma community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Vascular hamartoma.